Tricuspid atresia medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(30 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Template:Tricuspid atresia}}
{{Template:Tricuspid atresia}}
{{CMG}}; '''Associate Editor-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [[mailto:psingh@perfuse.org]]; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [[mailto:kfeeney@perfuse.org]]
{{CMG}}; '''Associate Editor-In-Chief:''' {{Sara.Zand}}[[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu]


Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


==Overview==
==Overview==
The mainstay of therapy for the cyanotic neonate with severe  [[ pulmonary stenosis]] and small-sized  [[VSD]] is using [[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]]. The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion]] and then starting [[ ACEI]].


==Medical Therapy==
===ACC/AHA Guidelines - Recommendations for Medical Therapy (DO NOT EDIT)===


{|class="wikitable"
== Medical Therapy ==
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''[[Warfarin]] should be given for patients who have a documented atrial shunt, atrial thrombus, atrial arrhythmias, or a thromboembolic event.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|}


{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''It is reasonable to treat systemic ventricle (SV) dysfunction with [[angiotensin-converting enzyme]] ([[ACE]]) inhibitors and diuretics.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|}


===ACC/AHA Guidelines - Recommendations for Management Strategies for the Patient with Prior Fontan Repair (DO NOT EDIT)===
*The mainstay of therapy for the cyanotic neonate with severe  [[ pulmonary stenosis]] and small-sized  [[VSD]] is using [[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]].<ref name="AkkinapallyHundalani2018">{{cite journal|last1=Akkinapally|first1=Smita|last2=Hundalani|first2=Shilpa G|last3=Kulkarni|first3=Madhulika|last4=Fernandes|first4=Caraciolo J|last5=Cabrera|first5=Antonio G|last6=Shivanna|first6=Binoy|last7=Pammi|first7=Mohan|title=Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions|journal=Cochrane Database of Systematic Reviews|year=2018|issn=14651858|doi=10.1002/14651858.CD011417.pub2}}</ref>
 
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Management of patients with prior Fontan repair should be coordinated with a regional ACHD center. Local cardiologists, internists, and family care physicians should develop ongoing relationships with such a center with continuous availability of specialists.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''a.'''At least yearly follow-up is recommended for patients after Fontan repair.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''b.'''[[Arrhythmia]] management is frequently an issue, and consultation with an electrophysiologist is recommended as a vital part of care.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''c.'''New-onset atrial tachyarrhythmia should prompt a comprehensive noninvasive imaging evaluation to identify associated atrial/baffle thrombus, anatomic abnormalities of the Fontan pathway, or ventricular dysfunction.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
|}


*The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion]] and then starting [[ ACEI]].


==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Needs content]]
 
[[Category:Cardiovascular system]]
[[Category:Cardiovascular system]]
[[Category:Cardiology]]
[[Category:Cardiology]]
Line 49: Line 24:
[[Category:Pediatrics]]
[[Category:Pediatrics]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Needs content]]
[[Category:Cardiovascular diseases]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 19:30, 8 November 2020

Tricuspid atresia Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Tricuspid Atresia from other Disorders

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenarios

Pregnancy

Case Studies

Case #1

Tricuspid atresia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tricuspid atresia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tricuspid atresia medical therapy

CDC on Tricuspid atresia medical therapy

Tricuspid atresia medical therapy in the news

Blogs on Tricuspid atresia medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Tricuspid atresia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2]Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

The mainstay of therapy for the cyanotic neonate with severe pulmonary stenosis and small-sized VSD is using prostaglandin E1 (PGE1) for keeping patency of ductus arteriosis. The mainstay of therapy for heart failure symptoms is using diuretic for reduction of congestion and then starting ACEI.


Medical Therapy

References

  1. ↑ Akkinapally, Smita; Hundalani, Shilpa G; Kulkarni, Madhulika; Fernandes, Caraciolo J; Cabrera, Antonio G; Shivanna, Binoy; Pammi, Mohan (2018). "Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD011417.pub2. ISSN 1465-1858.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Tricuspid_atresia_medical_therapy&oldid=1674638"